Financial Statement Analysis Project
turki99
BALANCESHEETS.docxVALEANT PHARMACEUTICALS INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(All dollar amounts expressed in millions of U.S. dollars)
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, |
||||||
|
|
|
2016 |
|
2015 (Restated) |
||||
|
Assets |
|
|
|
|
||||
|
Current assets: |
|
|
|
|
||||
|
Cash and cash equivalents |
|
$ |
597.3 |
|
|
$ |
322.6 |
|
|
Trade receivables, net |
|
2,686.9 |
|
|
2,075.8 |
|
||
|
Inventories, net |
|
1,256.6 |
|
|
889.2 |
|
||
|
Prepaid expenses and other current assets |
|
966.4 |
|
|
650.8 |
|
||
|
Deferred tax assets, net (Note 3) |
|
— |
|
|
193.3 |
|
||
|
Total current assets |
|
5,507.2 |
|
|
4,131.7 |
|
||
|
Property, plant and equipment, net |
|
1,441.8 |
|
|
1,312.3 |
|
||
|
Intangible assets, net |
|
23,083.0 |
|
|
11,277.9 |
|
||
|
Goodwill |
|
18,552.8 |
|
|
9,361.4 |
|
||
|
Deferred tax assets, net |
|
156.0 |
|
|
54.0 |
|
||
|
Other long-term assets, net |
|
223.7 |
|
|
167.4 |
|
||
|
Total assets |
|
$ |
48,964.5 |
|
|
$ |
26,304.7 |
|
|
Liabilities |
|
|
|
|
||||
|
Current liabilities: |
|
|
|
|
||||
|
Accounts payable |
|
$ |
433.7 |
|
|
$ |
398.0 |
|
|
Accrued and other current liabilities |
|
3,859.1 |
|
|
2,157.0 |
|
||
|
Acquisition-related contingent consideration |
|
196.8 |
|
|
141.8 |
|
||
|
Current portion of long-term debt |
|
823.0 |
|
|
0.9 |
|
||
|
Deferred tax liabilities, net (Note 3) |
|
— |
|
|
10.7 |
|
||
|
Total current liabilities |
|
5,312.6 |
|
|
2,708.4 |
|
||
|
Acquisition-related contingent consideration |
|
959.1 |
|
|
205.8 |
|
||
|
Long-term debt |
|
30,265.4 |
|
|
15,228.0 |
|
||
|
Pension and other benefit liabilities |
|
190.4 |
|
|
239.8 |
|
||
|
Liabilities for uncertain tax positions |
|
120.2 |
|
|
102.6 |
|
||
|
Deferred tax liabilities, net |
|
5,902.4 |
|
|
2,221.3 |
|
||
|
Other long-term liabilities |
|
184.6 |
|
|
197.1 |
|
||
|
Total liabilities |
|
42,934.7 |
|
|
20,903.0 |
|
||
|
Commitments and contingencies (Notes 21 and 22) |
|
|
|
|
||||
|
Equity |
|
|
|
|
||||
|
Common shares, no par value, unlimited shares authorized, 342,926,531 and |
|
|
|
|
||||
|
334,402,964 issued and outstanding at December 31, 2015 and 2014, respectively |
|
9,897.4 |
|
|
8,349.2 |
|
||
|
Additional paid-in capital |
|
304.9 |
|
|
243.9 |
|
||
|
Accumulated deficit |
|
(2,749.7 |
) |
|
(2,397.8 |
) |
||
|
Accumulated other comprehensive loss |
|
(1,541.6 |
) |
|
(915.9 |
) |
||
|
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity |
|
5,911.0 |
|
|
5,279.4 |
|
||
|
Noncontrolling interest |
|
118.8 |
|
|
122.3 |
|
||
|
Total equity |
|
6,029.8 |
|
|
5,401.7 |
|
||
|
Total liabilities and equity |
|
$ |
48,964.5 |
|
|
$ |
26,304.7 |
|
